Nephrotoxicity of intravenous colistin: a prospective evaluation.
Twenty-one patients who received intravenous colistimethate sodium (CMS) for at least 7 days for the treatment of multidrug-resistant Gram-negative bacterial infections were included in a prospective cohort study at 'Henry Dunant' Hospital in Athens, Greece. The mean (+/- standard deviation) and median daily doses, cumulative doses and duration of treatment of intravenous CMS were, respectively, 5.5 (+/- 1.9) and 6 million IU, 90.2 (+/- 52.0) and 72 million IU, and 17.7 (+/- 11.7) and 15 days (range 7-54 days). Three patients (14.3%) developed nephrotoxicity during treatment with CMS. The cumulative dose of administered CMS was statistically correlated with the difference in values of serum creatinine between the end and start of CMS treatment (r = 0.6, P = 0.004 by Spearman's test).
Falagas
Matthew E
ME
Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece. matthew.falagas@tufts.edu
Fragoulis
Konstantinos N
KN
Kasiakou
Sofia K
SK
Sermaidis
George J
GJ
Michalopoulos
Argyris
A
D058186:Acute Kidney Injury / Q000097:blood / Q000139:chemically induced* / Q000652:urine; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015331:Cohort Studies; D003091:Colistin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood / Q000652:urine; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006115:Greece; D006801:Humans; D007275:Injections, Intravenous; D007677:Kidney Function Tests; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome; D011446:Prospective Studies; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D003404:Creatinine; D003091:Colistin